BioWorld MedTech

March 30, 2016

China's Venus Medtech maintains lead in market for cardiac valve products

HONG KONG — Leading investment bank Goldman Sachs Group Inc. has injected $37 million into Chinese medical device company Venus Medtech (Hangzhou) Inc. after the creation of the first specialized cardiac valve research institute in China. Read More

Cancer paves the road for other companion diagnostics, but still a long way to go

Doc societies see six months of DAPT for latest DES devices

Cairn finds its way on difficult FDA pathway, launches gastric emptying breath test

Other news to note

Daily M&A

Financings

Appointments and advancements

Product briefs

MDD'S Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for April 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 4, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...

Immune checkpoint inhibitors illustration of PD-1, CTLA-4 and PD-L1.

Checkpoint inhibitor journey traces Chinese firms’ path to global revenue

BioWorld

Chinese pharmaceutical companies are making significant inroads into the global oncology market, particularly with the development and approval of immune...